Neoadjuvant Atezolizumab Yields High DFS in Muscle-Invasive Urothelial Cancer

Article

Neoadjuvant atezolizumab as a treatment for muscle-invasive urothelial cancer of the bladder yielded a high disease-free survival.

A high disease-free survival (DFS) and promising long-term outcomes were observed in patients with muscle-invasive urothelial cancer of the bladder following treatment with neoadjuvant atezolizumab (Tecentriq), according to a study published in European Urology.

The 2-year DFS was 68% (95% CI, 58%-76%) and the overall survival was 77% (95% CI, 68%-85%) following treatment with neoadjuvant atezolizumab. Patients had a partial complete response (pCR) rate of 31% (95% CI, 21%-41%), and the 2-year DFS for patients who achieved pCR was 85% (95% CI, 65%-94%). The relapse-free survival (RFS) did not correlate with baseline PD-L1 (HR, 0.60; 95% CI, 0.24-1.50; P = .26) or tumor mutational burden (HR, 0.72; 95% CI, 0.31-1.70; P = .46). RFS was correlated with high baseline stromal CD8 positivity (HR, 0.25; 95% CI, 0.09-0.68; P = .007) and high post-treatment fibroblast activation protein (HR, 4.1; 95% CI, 1.3-13.0; P = .01).

A total of 95 patients enrolled on the study, 87 of whom received a radical cystectomy. In terms of baseline characteristics, 74% of patients had T2 disease and 75% had an ECOG score of 0. The median follow-up was 25 months (95% CI, 25-26). Overall, 22 patients relapsed or died from relapse, and 22 died due to any cause. During treatment and the surgical period, there were 3 non-cancer-related deaths from non-treatment-related aspiration pneumonia, immune-related myocardial infarction, and cardiogenic shock.

Poor DFS was correlated with several factors, including higher T stage at baseline (HR, 2.4; 95% CI, 1.0-5.6; P = .045), cystectomy (HR, 13.0; 95% CI, 3.7-43.0; P <.001), and node-positive disease at surgery (HR, 6.6; 95% CI, 2.4-18.0).

In post-treatment samples, investigators noticed an increase of CD39/CD8-positive T cells in responding tumors (P <.05). There was a loss of major histocompatibility class (MHC) I in 11% of samples. However, there was no statistically significant correlation between MHC class I loss and response or relapse. Additionally, high MHC class I at baseline was not a predictor of increased RFS (HR, 2.3; 95% CI, 0.30-17.0; P = .424).

There was no association between FOXP3 at baseline and relapse (rate ratio, 0.87; 95% CI, 0.37-2.0; P = .74) or RFS (HR, 0.86; 95% CI, 0.33-2.2; P = .75), although it was correlated with response before and after treatment. Additionally, there was a positive correlation between baseline CD8 and FOXP3 expression (r = .40).

At baseline, 63% of patients were circulating tumor DNA (ctDNA) positive at baseline, which was significantly associated with increased PD-L1 expression in the tumor-infiltrating immune cell, with 5% or more of immune cells (P = .008) and tumor cell staining with 5% or more of tumor cells (P = .007). A total of 47% of patients were ctDNA positive at the post-neoadjuvant timepoint, which significantly correlated with lymph node status (P = .02) and T stage at surgery (P = .0005) and T stage at surgery (P = .0005). During the post-cystectomy timepoint, 14% of patients were ctDNA positive.

Among the patients who were ctDNA positive at baseline and became ctDNA negative after surgery (n = 3), all achieved a pCR after surgery, in addition to 2 other patients who were ctDNA positive at baseline and the post-neoadjuvant timepoint who cleared their ctDNA following surgery.

Patients during the post-surgery timepoint who were ctDNA positive had higher rates of relapse than those who were ctDNA negative (HR, 78; P <.001). Investigators did not observe relapse events for patients who were ctDNA negative at baseline and at the post-neoadjuvant time point. Additionally, those who were PD-1–positive were more often ctDNA positive, and outcomes were poor for those who were ctDNA positive and PD-L1-negative.

Reference

Szabados B, Kockx M, Assaf ZJ, et al. Final results of neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive urothelial cancer of the bladder. Eur Urol. Published online May 14, 2022. doi:10.1016/j.eururo.2022.04.013

Recent Videos
Other ongoing urothelial cancer trials are assessing enfortumab vedotin–based combinations in the neoadjuvant setting.
Approximately 95% of those with a complete response to enfortumab vedotin plus pembrolizumab were alive after 2 years in the phase 3 EV-302 trial.
Thomas Powles, MBBS, MRCP, MD, highlighted fatigue, nausea, and peripheral neuropathy as toxicities observed with enfortumab vedotin plus pembrolizumab.
Updated findings from the phase 3 EV-302 trial show enduring responses and survival improvements with enfortumab vedotin plus pembrolizumab.
Karine Tawagi, MD, and Sia Daneshmand, MD, with the Oncology Brothers presenting slides
Karine Tawagi, MD, and Sia Daneshmand, MD, with the Oncology Brothers presenting slides
Related Content